Earn CME Credit in Upcoming Activity Titled: The Role Of Biologics for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Release Date: August 14, 2020; Expiration Date: August 13, 2021

Nasal polyps impact an estimated 13 million Americans. In particular, nasal polyps affect 45% of people with adult-onset asthma and approximately 30% of people with chronic rhinosinusitis, in the latter, it is known as chronic rhinosinusitis with nasal polyps (CRSwNP). The heterogeneity of CRSwNP may explain the recurrence of nasal polyps and the limitations of a “one size fits all” medical and surgical approach for the treatment for CRSwNP. The development of biologics targeting various aspects of chronic inflammation for the treatment of CRSwNP is evolving rapidly. This program discusses the prevalence and underlying pathophysiology of CRSwNP and the clinical trial data on emerging therapeutics options based on their mechanisms of action, efficacy, and safety data. 

Target Audience

This initiative is intended for otolaryngologists (ENTs) interested in better understanding the role of biologics in reducing inflammation and related symptomatology in ENT disorders, especially nasal polyposis.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

• Describe the prevalence and underlying pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP)
• Review the emerging biologic targets and treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
• Evaluate the clinical trial data on emerging therapeutics options for chronic rhinosinusitis with nasal polyps (CRSwNP) based on their mechanisms of action, efficacy, and safety data

Accreditation

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Criteria for Success

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

For more information and to participate in the activity please http://aaoacme.org/